<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05119075</url>
  </required_header>
  <id_info>
    <org_study_id>2021-01608</org_study_id>
    <nct_id>NCT05119075</nct_id>
  </id_info>
  <brief_title>Psychological Effects of Levodopa in Parkinson's Disease</brief_title>
  <official_title>Unravelling the Impact of Levodopa on Dysfunctional Brain Networks in Parkinson's Disease With Neuropsychiatric Fluctuations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Inselspital, Berne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospital, Geneva</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ecole Polytechnique Fédérale de Lausanne</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital Inselspital, Berne</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators aim is to study neuropsychiatric symptoms and underlying abnormalities in&#xD;
      resting-state fMRI in patients with Parkinson's disease (PD) suffering from neuropsychiatric&#xD;
      fluctuations, to enhance the understanding of the pathophysiological mechanisms underlying&#xD;
      neuropsychiatric symptoms.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Parkinson's disease (PD) is primarily classified and known as a movement disorder&#xD;
      characterized by tremor, bradykinesia and rigidity. However, clinical examination and&#xD;
      research have shown that PD extensively affects other systems as well, giving rise to&#xD;
      non-motor symptoms (NMS) such as anxiety, sleep disorders, apathy, depression, cognitive&#xD;
      impairment, and hallucinations. These non-motor fluctuations (NMF) represent a main source of&#xD;
      disability in PD and among those, neuropsychiatric fluctuations are the most frequent. During&#xD;
      the dopaminergic OFF-drug state anxiety, apathy, and depression are common, whereas during&#xD;
      the dopaminergic ON-drug state euphoria, well-being, impulse control disorders (ICD) and&#xD;
      other behavioral addictions, mania, and psychosis might occur.&#xD;
&#xD;
      Despite the severe consequences associated with dopaminergic modulation, the understanding of&#xD;
      the pathophysiological mechanisms of neuropsychiatric symptoms is still limited and better&#xD;
      detection and more effective treatments are needed. Fluctuating PD is a very powerful model&#xD;
      allowing to study opposite psychiatric states intra-individually in both levodopa&#xD;
      dopaminergic ON- and OFF-drug state, allowing to abstract many interpersonal variables.&#xD;
&#xD;
      Neurotechnology and advanced neuroimaging techniques can improve the understanding of the&#xD;
      neural basis and brain mechanisms of specific neuropsychiatric symptoms in PD. In particular,&#xD;
      dynamic functional connectivity (FC) analysis characterizes functional abnormalities from&#xD;
      resting state (rs)-fMRI not only in terms of brain activations, but also of whole-brain&#xD;
      functional networks and the transitions between maps of activations. The temporal evolution&#xD;
      of these networks, assessed with dynamic FC approaches, has recently shown to be relevant in&#xD;
      several clinical contexts.&#xD;
&#xD;
      Therefore, the investigators long-term goal is to identify specific resting-state&#xD;
      signatures/biomarkers for the individual neuropsychiatric PD symptoms related to disease in&#xD;
      dopaminergic OFF-drug state (depression, anxiety, apathy, fatigue, shame, bradyphrenia) and&#xD;
      to dopaminergic treatment in dopaminergic ON-drug state (mania, impulse control disorders,&#xD;
      hallucinations, psychosis, creative thinking), which might be used in the future as a proxy&#xD;
      for the measurement of neuropsychiatric symptoms/fluctuations and thus to assess the&#xD;
      effectiveness of specific therapies.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Correlation of functional connectivity abnormalities with neuropsychiatric fluctuations</measure>
    <time_frame>≤ 6 weeks</time_frame>
    <description>Score on the Neuropsychiatric Fluctuations Scale (NFS)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Correlation of functional connectivity abnormalities with shame</measure>
    <time_frame>≤ 6 weeks</time_frame>
    <description>Score on the Shame Visual Analogic Scale</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Correlation of functional connectivity abnormalities with hallucinations</measure>
    <time_frame>≤ 6 weeks</time_frame>
    <description>Score on robot-induced presence hallucination (PH) ratings</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Correlation of functional connectivity abnormalities with bradyphrenia</measure>
    <time_frame>≤ 6 weeks</time_frame>
    <description>Score on the Bradyphrenia Scale</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Correlation of functional connectivity abnormalities with creativity</measure>
    <time_frame>≤ 6 weeks</time_frame>
    <description>Score on the Creative Thinking Scale</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The role of dopamine on hallucinations</measure>
    <time_frame>≤ 6 weeks</time_frame>
    <description>Score on robot-induced presence hallucination (PH) ratings in dopaminergic ON- and OFF-drug state.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The role of dopamine on creativity</measure>
    <time_frame>≤ 6 weeks</time_frame>
    <description>Score on the Creative Thinking Scale in dopaminergic ON- and OFF-drug state.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The role of dopamine on shame</measure>
    <time_frame>≤ 6 weeks</time_frame>
    <description>Score on the Shame Visual Analogic Scale in dopaminergic ON- and OFF-drug state.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The role of dopamine on bradyphrenia</measure>
    <time_frame>≤ 6 weeks</time_frame>
    <description>Score on the Bradyphrenia Scale in dopaminergic ON- and OFF-drug state.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Parkinson Disease</condition>
  <arm_group>
    <arm_group_label>Dopaminergic ON-drug state first, dopaminergic OFF-drug state second</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The following examinations and assessments will be performed at visit 3 on regular treatment in dopaminergic ON-drug state and at visit 4 in dopaminergic OFF-drug state (overnight withdrawal of all antiparkinsonian drugs):&#xD;
MRI assessment,&#xD;
Cognitive, neuropsychiatric and neurological assessment,&#xD;
Robot-induced hallucinations through sensorimotor stimulation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dopaminergic OFF-drug state first, dopaminergic ON-drug state second</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The following examinations and assessments will be performed at visit 3 in dopaminergic OFF-drug state (overnight withdrawal of all antiparkinsonian drugs) and at visit 4 on regular treatment in dopaminergic ON-drug state:&#xD;
MRI assessment,&#xD;
Cognitive, neuropsychiatric and neurological assessment,&#xD;
Robot-induced hallucinations through sensorimotor stimulation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Dopaminergic OFF-drug state</intervention_name>
    <description>Dopaminergic OFF-drug state: Overnight withdrawal of dopaminergic antiparkinsonian drugs during visit 3 or 4. The sequence of drug conditions (dopaminergic OFF-drug/ON-drug state or ON-drug/OFF-drug state) will be randomized.</description>
    <arm_group_label>Dopaminergic OFF-drug state first, dopaminergic ON-drug state second</arm_group_label>
    <arm_group_label>Dopaminergic ON-drug state first, dopaminergic OFF-drug state second</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Dopaminergic ON-drug state</intervention_name>
    <description>Dopaminergic ON-drug state: Patient will be evaluated in his/her regular treatment in dopaminergic ON-drug state at visit 3 or 4. The sequence of drug conditions (dopaminergic OFF-drug/ON-drug state or ON-drug/OFF-drug state) will be randomized.</description>
    <arm_group_label>Dopaminergic OFF-drug state first, dopaminergic ON-drug state second</arm_group_label>
    <arm_group_label>Dopaminergic ON-drug state first, dopaminergic OFF-drug state second</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adults above 18 years old&#xD;
&#xD;
          -  Male or female&#xD;
&#xD;
          -  Diagnosed with Parkinson's disease&#xD;
&#xD;
          -  Able to understand instructions, neuropsychological tests and provide written informed&#xD;
             consent&#xD;
&#xD;
          -  Able to understand the locally used language of the experimental site and speak&#xD;
             fluently&#xD;
&#xD;
          -  Presence of neuropsychiatric fluctuations, defined as the sum ≥ 3 of items included in&#xD;
             the Ardouin Scale of Behaviour in Parkinson's Disease (ASBPD) part 2&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Structural brain disease other than Parkinson's disease&#xD;
&#xD;
          -  Substance abuse and/or dependence (other than DRT)&#xD;
&#xD;
          -  Ongoing depression with suicidal ideation&#xD;
&#xD;
          -  Severe tremors/dyskinesia/ interfering with MRI performance&#xD;
&#xD;
          -  Participating in a pharmacological study&#xD;
&#xD;
          -  Inability to provide informed consent (legal guardianship)&#xD;
&#xD;
          -  MRI contraindications&#xD;
&#xD;
          -  Pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul Krack, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Inselspital, Berne</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Paul Krack, Prof.</last_name>
    <phone>031 632 21 68</phone>
    <phone_ext>+41</phone_ext>
    <email>paul.krack@insel.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marie Elise Maradan</last_name>
    <phone>031 632 63 62</phone>
    <phone_ext>+41</phone_ext>
    <email>marie.maradan@insel.ch</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital Inselspital, Berne</name>
      <address>
        <city>Bern</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <contact>
      <last_name>Paul Krack, Prof.</last_name>
      <phone>031 632 21 68</phone>
      <phone_ext>+41</phone_ext>
      <email>paul.krack@insel.ch</email>
    </contact>
    <contact_backup>
      <last_name>Marie Elise Maradan</last_name>
      <phone>031 632 63 62</phone>
      <phone_ext>+41</phone_ext>
      <email>marie.maradan@insel.ch</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>EPFL Campus Biotech</name>
      <address>
        <city>Geneva</city>
        <zip>1202</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <contact>
      <last_name>Olaf Blanke, Prof.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>EPFL Institute of Bioengineering</name>
      <address>
        <city>Geneva</city>
        <zip>1202</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Geneva (HUG)</name>
      <address>
        <city>Geneva</city>
        <zip>1205</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <contact>
      <last_name>Vanessa Fleury, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>September 28, 2021</study_first_submitted>
  <study_first_submitted_qc>November 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 12, 2021</study_first_posted>
  <last_update_submitted>November 2, 2021</last_update_submitted>
  <last_update_submitted_qc>November 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Neuropsychiatric fluctuations</keyword>
  <keyword>Creativity</keyword>
  <keyword>Shame</keyword>
  <keyword>Embarrassment</keyword>
  <keyword>Non-motor symptoms</keyword>
  <keyword>Hallucinations</keyword>
  <keyword>Bradyphrenia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dopamine</mesh_term>
    <mesh_term>Dopamine Agonists</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

